Cancer drug developer immatics biotechnologies prides itself on open communication. Using IntraLinks to manage due diligence, immatics showed investors they could trust the company. What resulted was the largest private biotech financing round in Germany since 2001. In the process, immatics saved time and resources, and gave investors an efficient way to review information.

"Without IntraLinks, the process would have taken at least twice as long. No doubt we saved a man month of resources using IntraLinks and used our staff more productively." Joerg Scheidle, Chief Financial Officer, immatics biotechnologies

To read the complete case study please click here.